IDH1 and acute myeloid leukemia: In FLT3-co-mutated disease, add FLT3 inhibitors (e.g., gilteritinib), as shown in a 2024 trial achieving 60% CR/CRh rates in IDH1/FLT3-mutant AML (Short et al., 2024).